Standout Papers

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus 2020 2026 2022 2024222
  1. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus (2020)
    Kenji Kabashima, Hiroshi Komazaki et al. New England Journal of Medicine

Immediate Impact

44 standout
Sub-graph 1 of 17

Citing Papers

Mucosal immune response in biology, disease prevention and treatment
2025 Standout
Therapeutic effect of bosentan on 2, 4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis mouse model
2025 Standout
4 intermediate papers

Works of Hiroshi Komazaki being referenced

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*
2021
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
2020 Standout

Author Peers

Author Last Decade Papers Cites
Hiroshi Komazaki 292 103 22 217 9 360
Lena Hagströmer 255 63 27 114 13 340
Koichi Mitsuishi 266 99 51 146 8 403
Sadaf Kasraie 287 80 46 143 8 373
Sonja Grundmann 261 48 12 138 16 393
Étienne Saint‐Cyr Proulx 311 105 34 208 15 382
Lauren Becker 286 164 13 200 7 365
Nick Othlinghaus 233 73 25 121 10 352
Sho Hanakawa 203 98 25 124 10 353
Girish C. Mohan 213 64 20 103 13 336
U. Darsow 215 118 11 223 8 375

All Works

Loading papers...

Rankless by CCL
2026